Skip to main content
SpringerLink
Log in

Aspirin resistance in atherosclerosis

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Clinically, aspirin resistance is defined as the failure of aspirin therapy to prevent an acute vascular thrombotic event despite regular intake of appropriate doses. In the laboratory, aspirin resistance encompasses the drug’s failure to attain a particular level of platelet inhibition. From a clinical standpoint, the inability of aspirin to prevent a thrombotic event, despite appropriate cyclooxygenase-1 inhibition, implies the involvement of other factors. Evidence is emerging that aspirin resistance, as defined by residual platelet activity, merely reflects an individual’s enhanced basal platelet function and suggests a hereditary component. Due to the multifactorial nature of cardiovascular disease, it is likely that a single therapy like aspirin cannot fully treat and prevent all thrombotic complications in the setting of atherosclerosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rosamond W, Flegal K, Friday G, et al.: Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115:e69–e171.

    Article  PubMed  Google Scholar 

  2. Awtry EH, Loscalzo J: Aspirin. Circulation 2000, 101:1206–1218.

    PubMed  CAS  Google Scholar 

  3. Craven L: Experiences with aspirin (acetylsalicylic acid) in the non-specific prophylaxis of coronary thrombosis. Miss Valley Med J 1953, 75:38–44.

    PubMed  CAS  Google Scholar 

  4. Mason PJ, Jacobs AK, Freedman JE: Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 2005, 46:986–993.

    Article  PubMed  CAS  Google Scholar 

  5. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71–86.

  6. Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.

    Article  PubMed  CAS  Google Scholar 

  7. Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411–2420.

    Article  PubMed  CAS  Google Scholar 

  8. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 1993, 71:397–403.

    Article  PubMed  CAS  Google Scholar 

  9. Buchanan MR, Schwartz L, Bourassa M, et al.: Results of the BRAT study-a pilot study investigating the possible significance of ASA non-responsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery. Can J Cardiol 2000, 16:1385–1390.

    PubMed  CAS  Google Scholar 

  10. Andersen K, Hurlen M, Arnesen H, Seljeflot I: Aspirin nonresponsiveness as measured by PFA-100 in patients with coronary artery disease. Thromb Res 2002, 108:37–42.

    Article  PubMed  Google Scholar 

  11. Eikelboom JW, Hirsh J, Weitz JI, et al.: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105:1650–1655.

    Article  PubMed  CAS  Google Scholar 

  12. Gum PA, Kottke-Marchant K, Welsh PA, et al.: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961–965.

    Article  PubMed  CAS  Google Scholar 

  13. Cotter G, Shemesh E, Zehavi M, et al.: Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J 2004, 147:293–300.

    Article  PubMed  CAS  Google Scholar 

  14. Pamukcu B, Oflaz H, Oncul A, et al.: The role of aspirin resistance on outcome in patients with acute coronary syndrome and the effect of clopidogrel therapy in the prevention of major cardiovascular events. J Thromb Thrombolysis 2006, 22:103–110.

    Article  PubMed  CAS  Google Scholar 

  15. Stejskal D, Vaclavik J, Lacnak B, Proskova J: Aspirin resistance measured by cationic propyl gallate platelet aggregometry and recurrent cardiovascular events during 4 years of follow-up. Eur J Intern Med 2006, 17:349–354.

    Article  PubMed  CAS  Google Scholar 

  16. Chen WH, Cheng X, Lee PY, et al.: Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med 2007, 120:631–635.

    Article  PubMed  CAS  Google Scholar 

  17. Patrono C, Coller B, Dalen JE, et al.: Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001, 119:39S–63S.

    Article  PubMed  CAS  Google Scholar 

  18. Rocca B, Secchiero P, Ciabattoni G, et al.: Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci U S A 2002, 99:7634–7639.

    Article  PubMed  CAS  Google Scholar 

  19. Maree AO, Fitzgerald DJ: Aspirin and coronary artery disease. Thromb Haemost 2004, 92:1175–1181.

    PubMed  CAS  Google Scholar 

  20. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982, 69:1366–1372.

    Article  PubMed  CAS  Google Scholar 

  21. Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD: Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007, 120:323–336.

    Article  PubMed  CAS  Google Scholar 

  22. Freedman JE: Heritability, platelet function, and aspirin: a link established but cause unknown. Circulation 2007, 115:2468–2470.

    Article  PubMed  Google Scholar 

  23. Freedman JE: CD40-CD40L and platelet function: beyond hemostasis. Circ Res 2003, 92:944–946.

    Article  PubMed  CAS  Google Scholar 

  24. Cattaneo M: Laboratory detection of ‘aspirin resistance’: what test should we use (if any)? Eur Heart J 2007, 28:1673–1675.

    Article  PubMed  Google Scholar 

  25. Mehta J, Mehta P, Burger C, Pepine CJ: Platelet aggregation studies in coronary artery disease. Part 4. Effect of aspirin. Atherosclerosis 1978, 31:169–175.

    Article  PubMed  CAS  Google Scholar 

  26. Cheng X, Chen WH, Simon DI: Aspirin resistance or variable response or both? Am J Cardiol 2006, 98:11N–17N.

    Article  PubMed  CAS  Google Scholar 

  27. Hovens MM, Snoep JD, Eikenboom JC, et al.: Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175–181.

    Article  PubMed  CAS  Google Scholar 

  28. Snoep JD, Hovens MM, Eikenboom JC, et al.: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007, 167:1593–1599.

    Article  PubMed  Google Scholar 

  29. Undas A, Brummel-Ziedins KE, Mann KG: Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007, 109:2285–2292.

    Article  PubMed  CAS  Google Scholar 

  30. Schwartz KA, Schwartz DE, Ghosheh K, et al.: Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 2005, 95:973–975.

    Article  PubMed  CAS  Google Scholar 

  31. Faraday N, Yanek LR, Mathias R, et al.: Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007, 115:2490–2496.

    Article  PubMed  CAS  Google Scholar 

  32. Kurth T, Glynn RJ, Walker AM, et al.: Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191–1195.

    Article  PubMed  CAS  Google Scholar 

  33. Alexander JH, Harrington RA, Tuttle RH, et al.: Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 1999, 83:1147–1151.

    Article  PubMed  CAS  Google Scholar 

  34. Pulcinelli FM, Pignatelli P, Celestini A, et al.: Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol 2004, 43:979–984.

    Article  PubMed  CAS  Google Scholar 

  35. Cox D, Maree AO, Dooley M, et al.: Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke 2006, 37:2153–2158.

    Article  PubMed  CAS  Google Scholar 

  36. Maree AO, Curtin RJ, Dooley M, et al.: Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 2005, 46:1258–1263.

    Article  PubMed  CAS  Google Scholar 

  37. Tamminen M, Lassila R, Westerbacka J, et al.: Obesity is associated with impaired platelet-inhibitory effect of acetylsalicylic acid in nondiabetic subjects. Int J Obes Relat Metab Disord 2003, 27:907–911.

    Article  PubMed  CAS  Google Scholar 

  38. Guthikonda S, Lev EI, Patel R, et al.: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Thromb Haemost 2007, 5:490–496.

    Article  PubMed  CAS  Google Scholar 

  39. Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004, 24:246–255.

    Article  PubMed  CAS  Google Scholar 

  40. Modica A, Karlsson F, Mooe T: Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost 2007, 5:507–511.

    Article  PubMed  CAS  Google Scholar 

  41. Freedman JE: The aspirin resistance controversy: clinical entity or platelet heterogeneity? Circulation 2006, 113:2865–2867.

    Article  PubMed  Google Scholar 

  42. Undas A, Placzkiewicz-Jankowska E, Zielinski L, Tracz W: Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. Thromb Haemost 2007, 97:1056–1058.

    PubMed  CAS  Google Scholar 

  43. Homoncik M, Jilma B, Eichelberger B, Panzer S: Inhibitory activity of aspirin on von Willebrand factor-induced platelet aggregation. Thromb Res 2000, 99:461–466.

    Article  PubMed  CAS  Google Scholar 

  44. Kuliczkowski W, Kobusiak-Prokopowicz M, Prajs I, et al.: Aspirin failure course during exercise and its connection with soluble CD40L. Thromb Res 2007, 119:679–686.

    Article  PubMed  CAS  Google Scholar 

  45. Frelinger AL 3rd, Furman MI, Linden MD, et al.: Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1-and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006, 113:2888–2896.

    Article  PubMed  CAS  Google Scholar 

  46. Takahashi S, Ushida M, Komine R, et al.: Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007, 119:517–524.

    Article  PubMed  CAS  Google Scholar 

  47. O’Donnell CJ, Larson MG, Feng D, et al.: Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001, 103:3051–3056.

    PubMed  CAS  Google Scholar 

  48. Takahashi S, Ushida M, Komine R, et al.: Platelet responsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms. Thromb Res 2007, [Epub ahead of print].

  49. Maree AO, Curtin RJ, Chubb A, et al.: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005, 3:2340–2345.

    Article  PubMed  CAS  Google Scholar 

  50. Matetzky S, Shenkman B, Guetta V, et al.: Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171–3175.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Boston University School of Medicine, 700 Albany Street, W507, Boston, MA, 02118, USA

    Jane E. Freedman

Authors
  1. Price Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jane E. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jane E. Freedman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blair, P., Freedman, J.E. Aspirin resistance in atherosclerosis. Curr Atheroscler Rep 10, 149–157 (2008). https://doi.org/10.1007/s11883-008-0022-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-008-0022-2

Keywords

Search

Navigation